Caplin Point Laboratories Ltd.

BSE: CAPLIPOINT524742ISIN INE475E01026

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹2,747.85+152.40 (+5.87%)

as of 18 Sep 2026

52W high: ₹2,874.00
52W low: ₹1,502.45
Off 52W high: -4.39%
1M return: +6.88%
3M return: +9.64%
6M return: +71.28%
1Y return: +18.45%
20D avg volume: 20,669
50 DMA: ₹2,602.13
200 DMA: ₹2,078.23

Key ratios Consolidated

Market cap: ₹20,887 Cr
Current price: ₹2,747.85
52W high / low: ₹2,874.00 / ₹1,502.45
Face value: ₹2.00
P/E: 30.80
P/B: —
EPS (TTM): ₹89.20
Book value / share: —
ROE: —
ROCE: 22.00%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-93.61 Cr
Interest cover: 923.75
Dividend yield: 0.29%
Dividend / share (TTM): ₹8.00
Payout: 8.97%
Cash conversion cycle: 160.0 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	610.36	600.16	542.77	534.04	510.22	502.45	492.96	483.10	458.96	453.22	435.50	410.06
	33.55	28.36	33.68	30.37	23.14	25.74	31.36	20.77	18.56	17.29	17.18	20.43
	418.68	415.08	372.54	363.43	348.93	351.60	347.05	335.31	323.16	324.54	307.30	284.60
	107.06	102.11	89.24	92.34	73.51	60.84	59.80	69.23	63.65	57.87	50.95	66.85
	196.36	209.02	128.00	121.68	113.50	138.77	139.43	122.33	74.48	121.78	179.77	129.33
	54.13	52.62	49.78	47.23	43.16	46.51	46.77	44.29	40.15	36.77	36.67	35.08
	0.18	0.36	0.18	0.16	0.18	0.17	0.18	0.21	0.05	0.15	0.17	0.18
	21.62	18.80	19.28	18.40	16.29	17.04	16.20	16.76	15.96	16.40	13.90	11.77
	97.55	98.30	88.16	87.34	94.06	86.68	88.55	85.23	81.52	79.85	66.44	73.48
	225.23	213.44	203.91	200.98	184.43	176.59	177.27	168.56	154.36	145.97	145.38	145.89
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.00	0.00
	225.23	213.44	203.91	200.98	184.43	176.59	177.27	168.56	154.36	146.03	145.38	145.89
	46.13	40.56	38.03	40.77	33.70	31.39	37.19	37.65	29.46	24.80	25.58	29.86
	179.09	172.88	165.86	160.23	150.76	145.28	140.07	130.81	124.92	121.23	119.83	116.14
	23.27	22.38	21.56	20.32	20.10	18.75	18.28	17.22	16.32	16.01	15.44	15.13
Key metrics
	247.03	232.60	223.37	219.54	200.90	193.80	193.65	185.53	170.37	162.58	159.45	157.84
	40.50%	38.80%	41.20%	41.10%	39.40%	38.60%	39.30%	38.40%	37.10%	35.90%	36.60%	38.50%
	29.30%	28.80%	30.60%	30.00%	29.50%	28.90%	28.40%	27.10%	27.20%	26.70%	27.50%	28.30%
	—	5.80%	—	6.20%	—	6.10%	—	—	—	—	—	—
	19.60%	19.40%	10.10%	10.50%	11.20%	10.90%	13.20%	17.80%	—	—	—	—
	18.80%	19.00%	18.40%	22.50%	20.70%	19.80%	16.90%	12.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	2,287	2,187	1,937	1,694	1,467	1,269	1,061	863.20	648.69	539.84	405.10
	125.96	115.54	96.43	66.94	55.98	38.75	23.54	41.33	19.03	12.66	6.39
	1,570	1,500	1,357	1,197	1,071	922.34	771.21	635.07	440.84	364.13	289.70
	390.75	357.20	248.45	239.81	223.04	192.31	129.82	108.12	95.12	90.22	64.78
	655.06	572.20	575.70	558.92	519.03	397.13	259.57	500.14	203.73	150.35	—
	203.76	199.15	177.72	143.59	136.99	115.30	102.53	67.76	47.11	39.14	—
	0.88	0.87	0.61	0.78	0.78	0.70	1.59	0.32	0.06	0.06	0.13
	78.10	72.77	65.96	53.44	44.99	46.90	36.97	31.62	23.43	—	—
	371.35	361.51	341.98	274.89	225.47	201.93	158.38	122.21	81.47	67.75	—
	843.56	802.75	676.79	564.16	451.27	385.82	313.62	269.46	226.88	188.38	121.78
	0.00	0.04	0.00	0.27	0.08	0.00	0.00	0.00	0.00	0.00	0.00
	843.56	802.79	676.79	564.43	451.35	385.82	313.62	269.46	226.88	188.38	121.78
	165.49	153.06	135.69	103.01	74.36	77.37	62.18	54.38	50.32	43.74	25.73
	678.06	649.73	541.09	461.42	376.99	308.45	251.44	215.08	176.56	144.63	96.05
	87.53	84.36	70.57	60.19	49.62	39.61	32.03	28.42	23.35	—	—
Key metrics
	922.54	876.43	743.36	618.65	497.12	433.42	352.18	301.40	250.37	188.44	121.91
	40.33%	40.10%	38.40%	36.50%	33.90%	34.10%	33.20%	34.90%	38.60%	34.90%	30.10%
	29.64%	29.70%	27.90%	27.20%	25.70%	24.30%	23.70%	24.90%	27.20%	26.80%	23.70%
	—	22.00%	23.30%	—	—	—	—	—	—	—	—
	—	12.90%	14.40%	15.50%	15.50%	19.60%	22.90%	33.10%	20.20%	33.30%	—
	—	20.10%	17.30%	22.40%	22.20%	22.70%	16.90%	21.80%	22.10%	50.60%	—
	—	275.10	240.85	—	—	—	—	—	—	—	—
	—	0.81	0.80	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-93.61	-198.90	—	—	—	—	—	—	—	—
	—	160.0	141.5	—	—	—	—	—	—	—	—
Balance sheet
	—	4,045	3,209	—	—	—	—	—	—	—	—
	—	2,586	2,134	—	—	—	—	—	—	—	—
	—	94.18	199.45	—	—	—	—	—	—	—	—
	—	825.81	632.49	—	—	—	—	—	—	—	—
	—	428.86	336.10	—	—	—	—	—	—	—	—
	—	250.07	205.25	—	—	—	—	—	—	—	—
	—	547.49	530.32	—	—	—	—	—	—	—	—
	—	296.03	217.58	—	—	—	—	—	—	—	—
	—	385.94	306.38	—	—	—	—	—	—	—	—
	—	0.57	0.55	—	—	—	—	—	—	—	—
	—	0.57	0.55	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	3,631	2,886	—	—	—	—	—	—	—	—
Cash flow
	—	523.23	432.37	—	—	—	—	—	—	—	—
	—	-582.29	-334.73	—	—	—	—	—	—	—	—
	—	-46.46	-38.32	—	—	—	—	—	—	—	—
	—	248.13	191.52	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	202.95	191.36	189.22	175.18	182.57	173.61	185.23	207.93	185.64	139.38	132.83	179.22
	62.79	61.08	31.73	59.22	32.03	41.25	28.83	43.01	21.50	36.18	17.90	24.49
	115.15	114.72	103.94	105.40	102.14	104.70	113.89	116.28	110.46	88.65	76.29	96.51
	42.12	45.80	39.47	34.92	38.62	34.25	33.29	32.72	36.38	40.18	43.43	45.84
	27.42	24.67	23.45	21.21	13.18	17.39	19.24	24.36	16.18	22.91	13.04	19.97
	13.73	13.15	13.41	11.54	9.63	14.39	13.89	12.99	10.86	9.77	9.52	9.10
	0.05	0.05	0.07	0.05	0.04	0.04	0.04	0.02	0.02	0.02	0.03	0.02
	6.56	6.90	6.37	6.02	6.14	6.09	6.01	6.49	6.18	6.93	6.76	6.72
	36.65	39.04	26.97	29.61	28.26	28.88	33.23	35.00	33.03	28.43	18.44	24.23
	150.59	137.72	117.01	129.00	112.46	110.16	100.17	134.66	96.68	86.91	74.43	107.19
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	150.59	137.72	117.01	129.00	112.46	110.16	100.17	134.66	96.68	86.91	74.43	107.19
	30.21	28.22	29.73	26.41	26.57	23.66	25.46	28.92	24.14	17.03	18.98	25.10
	120.38	109.50	87.28	102.59	85.89	86.50	74.71	105.74	72.54	69.88	55.45	82.09
	15.84	15.89	11.49	13.50	11.30	11.37	9.83	13.92	9.55	9.20	7.30	10.82
Key metrics
	157.20	144.67	123.45	135.07	118.64	116.29	106.22	141.17	102.88	93.86	81.22	113.93
	77.50%	75.60%	65.20%	77.10%	65.00%	67.00%	57.30%	67.90%	55.40%	67.30%	61.10%	63.60%
	59.30%	57.20%	46.10%	58.60%	47.00%	49.80%	40.30%	50.90%	39.10%	50.10%	41.70%	45.80%
	—	6.70%	—	7.00%	—	6.40%	—	—	—	—	—	—
	11.20%	10.20%	2.20%	-15.80%	-1.70%	24.60%	39.40%	16.00%	—	—	—	—
	40.20%	26.60%	16.80%	-3.00%	18.40%	23.80%	34.70%	28.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	758.71	738.33	752.41	625.09	528.61	528.06	482.68	527.83	536.91	426.57	347.72
	214.82	195.37	134.59	105.84	99.00	56.55	18.62	65.97	35.40	23.31	6.22
	439.21	426.18	445.33	365.19	334.46	334.30	291.36	340.67	369.65	303.83	260.53
	162.31	158.82	136.64	172.13	151.35	156.01	112.48	95.73	94.04	90.22	64.47
	96.75	82.51	77.17	76.77	48.38	57.64	82.92	143.18	145.50	92.28	97.34
	51.83	47.72	52.13	38.11	36.68	30.47	26.59	25.00	42.01	38.82	29.65
	0.22	0.20	0.12	0.10	0.12	0.09	0.17	0.18	0.06	0.06	0.13
	25.85	25.43	24.77	27.08	25.65	25.77	22.44	19.65	20.84	18.99	13.26
	132.27	123.87	130.14	94.68	—	73.32	47.33	57.66	69.70	65.85	—
	534.32	507.52	441.67	365.74	293.15	250.31	209.94	253.12	202.65	146.05	93.41
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	534.32	507.52	441.67	365.74	293.15	250.31	209.94	253.12	202.65	146.05	93.41
	114.57	110.94	102.18	82.03	58.89	62.44	53.71	55.49	54.49	43.74	22.55
	419.75	396.58	339.49	283.71	234.26	187.87	156.23	197.64	148.17	102.31	70.86
	56.72	52.17	44.67	37.36	30.89	24.82	20.65	26.13	19.60	—	—
Key metrics
	560.39	533.15	466.56	392.92	318.92	276.17	232.55	272.95	223.55	165.10	106.80
	73.86%	72.20%	62.00%	62.90%	60.30%	52.30%	48.20%	51.70%	41.60%	38.70%	30.70%
	55.32%	53.70%	45.10%	45.40%	44.30%	35.60%	32.40%	37.40%	27.60%	24.00%	20.40%
	—	24.60%	25.80%	—	—	—	—	—	—	—	—
	—	-1.90%	20.40%	18.30%	0.10%	9.40%	-8.60%	-1.70%	25.90%	22.70%	—
	—	16.80%	19.70%	21.10%	24.70%	20.30%	-21.00%	33.40%	44.80%	44.40%	—
	—	170.15	139.31	—	—	—	—	—	—	—	—
	—	0.54	0.58	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-44.09	-99.64	—	—	—	—	—	—	—	—
	—	127.8	87.6	—	—	—	—	—	—	—	—
Balance sheet
	—	2,212	1,814	—	—	—	—	—	—	—	—
	—	975.88	825.69	—	—	—	—	—	—	—	—
	—	44.09	99.64	—	—	—	—	—	—	—	—
	—	265.96	175.33	—	—	—	—	—	—	—	—
	—	85.66	66.26	—	—	—	—	—	—	—	—
	—	36.25	32.14	—	—	—	—	—	—	—	—
	—	219.68	201.59	—	—	—	—	—	—	—	—
	—	93.02	60.96	—	—	—	—	—	—	—	—
	—	144.17	99.85	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	2,050	1,701	—	—	—	—	—	—	—	—
Cash flow
	—	214.78	195.87	—	—	—	—	—	—	—	—
	—	-224.77	-140.20	—	—	—	—	—	—	—	—
	—	-45.81	-38.10	—	—	—	—	—	—	—	—
	—	44.63	56.56	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +11.78%
Sales CAGR 5Y: +8.87%
Sales CAGR 10Y: —
Profit CAGR 3Y: +19.18%
Profit CAGR 5Y: +20.48%
Profit CAGR 10Y: —
Sales YoY (TTM): +1.25%
Profit YoY (TTM): +18.96%

Consolidated

Sales CAGR 3Y: +14.25%
Sales CAGR 5Y: +15.56%
Sales CAGR 10Y: —
Profit CAGR 3Y: +19.89%
Profit CAGR 5Y: +20.91%
Profit CAGR 10Y: —
Sales YoY (TTM): +15.01%
Profit YoY (TTM): +19.60%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 70.59%

Holder	Type	Holding	Previous	Change
P VIJAYALAKSHMI	Promoter Group	24.71%	—	—
PAARTHIPAN C C	Promoter	18.64%	—	—
ASHOK GORKEY PARTHEEBAN	Promoter Group	11.91%	—	—
PARTHEEBAN VIVEK SIDDARTH	Promoter Group	11.85%	—	—
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	2.87%	—	—
MAY INDIA PROPERTY PRIVATE LIMITED	Promoter Group	2.79%	—	—
UTI MULTI CAP FUND	Public	1.81%	—	—
PINEBRIDGE GLOBAL FUNDS - PINEBRIDGE INDIA EQUITY FUND	Public	1.05%	—	—
FIRST DIMENSION HOLDINGS PRIVATE LIMITED	Promoter Group	0.49%	—	—
KIRAVIZ PROPERTIES AND CONSULTANCY LLP	Promoter Group	0.20%	—	—
KOTTESWARI B	Promoter Group	0.00%	—	—
CHELLAPPAN POOVALAMBEDU KANDASAMY	Promoter Group	0.00%	—	—
SOUNDARI B	Promoter Group	0.00%	—	—
VISALATCHI P	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Newspaper Publication for Notice of 35th AGM and E-Voting Information4 Sep 2026 · Company Update / Newspaper Publication
Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-264 Sep 2026 · Company Update / General
Business Responsibility and Sustainability Report for the Financial Year 2025-263 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 35th Annual General Meeting of the Company3 Sep 2026 · AGM/EGM / AGM
Annual Report for the Financial Year 2025-263 Sep 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Publication for convening 35th AGM of the Company through Video Conferencing.2 Sep 2026 · Company Update / Newspaper Publication
Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA1 Sep 2026 · Company Update / General
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)21 Aug 2026 · Company Update / General
Transcript for Earnings call- Q1- FY 2026-2719 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of Earnings call for the Quarter ended June 30, 202612 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for the Earnings Call for the Quarter ended June 30, 2026.12 Aug 2026 · Company Update / Investor Presentation
The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.12 Aug 2026 · Company Update / Change in Management
Financial Results for the quarter ended June 30, 202612 Aug 2026 · Result / Financial Results
Record date for Final Dividend is September 18, 202612 Aug 2026 · Corp. Action / Dividend
Board meeting outcome for meeting held on August 12, 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
Post-results conference call invite for the quarter ended June 30, 2026 is enclosed herewith.30 Jul 2026 · Company Update / Analyst / Investor Meet
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....29 Jul 2026 · Board Meeting / Board Meeting
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended June 30, 202611 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading Window commencing from July 01, 202627 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper advertisement for transfer of Unclaimed dividend and shares to IEPF22 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance report for the year ended March 31, 202629 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522 May 2026 · Company Update / Analyst / Investor Meet
Transcript for Earnings call- Q4- FY 2025-2621 May 2026 · Company Update / Earnings Call Transcript
Earnings call for Q4(2025-26)14 May 2026 · Company Update / Analyst / Investor Meet
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA, for Foscarnet Sodium Injection14 May 2026 · Company Update / Press Release / Media Release
The Board at its meeting held today, May 14, 2026, had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30, 2026.14 May 2026 · Corp. Action / Dividend
Financial Results for the Quarter and Year ended March 31, 202614 May 2026 · Result / Financial Results
The Board at its meeting held today, May 14, 2026, had 1. Approved the Audited standalone and consolidated financial results of the Company for the year ended March 31, 2026, along with ....14 May 2026 · Board Meeting / Outcome of Board Meeting
Q4 post-results conference call invite is enclosed herewith.7 May 2026 · Company Update / Analyst / Investor Meet
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited financial ....7 May 2026 · Board Meeting / Board Meeting
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for Calcium Gluconate Injection USP5 May 2026 · Company Update / Press Release / Media Release
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 20266 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading Window commencing from April 01, 202627 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA for the Potassium Phosphates Injection USP13 Mar 2026 · Company Update / Press Release / Media Release
Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3, 2026.3 Mar 2026 · Company Update / Cessation
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for the Desmopressin Acetate Injection USP28 Feb 2026 · Company Update / Press Release / Media Release
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Sodium Phosphates Injection USP24 Feb 2026 · Company Update / Press Release / Media Release
Transcript of the Earnings Call - Q3 - FY 2025-2611 Feb 2026 · Company Update / Earnings Call Transcript
Results - Analyst/Investor Meet - Earnings Call - Q3(2025-2026) - Audio Recording5 Feb 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for the quarter and nine months ended December 31, 20255 Feb 2026 · Company Update / Investor Presentation

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 4.0000	18 Sep 2026	18 Sep 2026	—
Interim Dividend - Rs. - 4.0000	29 May 2026	30 May 2026	—
Final Dividend - Rs. - 3.0000	12 Sep 2025	12 Sep 2025	—
Interim Dividend - Rs. - 3.0000	30 May 2025	30 May 2025	—
Final Dividend - Rs. - 2.5000	23 Sep 2024	—	—

Board meetings

12 Aug 2026 Board Meeting - Financial Results